Celecoxib Market Likely to Experience a Tremendous Growth in Near Future by 2020-2025 | Pfizer, Shire, Teva, Mylan, Chengdu Suncadia Pharma, Jiangsu Chiatai Qingjiang Pharma, Anhui Heyi Chemical

Celecoxib Market 2020 Global Industry research report studies latest Celecoxib industry aspects market size, share, trends, growth, business overview and Celecoxib industry scenario during the forecast period (2020-2025).

Overview of Global Celecoxib Market:

Celecoxib, sold under the brand name Celebrex among others, is a COX-2 selective nonsteroidal anti-inflammatory drug. It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. It may also be used to decrease the risk of colorectal adenomas in people with familial adenomatous polyposis. It is taken by mouth. Benefits are typically seen within an hour.

The report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the global Celecoxib market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/167652 .

Growth in the historic period resulted from economic growth in emerging markets, the rise in awareness of the benefits and developed nations towards Celecoxib costs and an increase in the number of medicine for serious side effects may include heart attacks, strokes, gastrointestinal perforation, gastrointestinal bleeding, kidney failure, and anaphylaxis.

Product Type Segmentation:
The Celecoxib market have different product type such as 50mg Celecoxib, 100mg Celecoxib, 200mg Celecoxib and 400mg Celecoxib. Celecoxib market product type gives treatment of painful menstruation, ankylosing spondylitis, juvenile rheumatoid arthritis, and to reduce the number of colon and rectal polyps in people with familial adenomatous polyposis.

Industry Segmentation:

Increasing instances across various sectors such as Rheumatoid Arthritis, Osteoarthritis, Acute Pain and Musculoskeletal Pain are raising the need of healthcare institutes, thereby raising the demand for Celecoxib market. This help in the profitable growth of the Global Celecoxib market in upcoming year.

Segmentation by Regions:

The Celecoxib market in North America has created medicine used in children with juvenile rheumatoid arthritis who are older than two years of age and weigh more than 10 kg (22 lb) in the world. It was followed by Western Europe, China, Japan, Southeast Asia, India and Central & South America regions. Asia Pacific is expected to record higher growth rate in Celecoxib Market during the forecast year.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Celecoxib Market Report 2020” @ https://www.businessindustryreports.com/buy-now/167652/single .

Top Leading Key Manufacturers are: Pfizer, Shire, Teva, Mylan, Chengdu Suncadia Pharmaceuticals, Jiangsu Chiatai Qingjiang Pharmaceutical, Anhui Heyi Chemical. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Top Industry News:

PFIZER AND BIONTECH ANNOUNCE EARLY POSITIVE UPDATE FROM GERMAN PHASE 1/2 COVID-19 VACCINE STUDY, INCLUDING FIRST T CELL RESPONSE DATA ON 20 JULY, 2020 -- BioNTech SE and Pfizer Inc. today announced initial data from their ongoing German Phase 1/2, open-label, non-randomized, non-placebo-controlled, dose-escalation trial, that is part of the global mRNA-based vaccine program against SARS-CoV-2. The data are available on an online preprint server at medrxiv and are concurrently undergoing scientific peer-review for potential publication.

The preliminary clinical results are for the most advanced investigational vaccine candidate in Pfizer’s and BioNTech’s BNT162 mRNA-based vaccine program against SARS-CoV-2, BNT162b1. This vaccine candidate is a lipid nanoparticle formulated, nucleoside-modified messenger RNA that encodes an optimized SARS-CoV-2 receptor binding domain (RBD) antigen. Overall, the new preliminary data from this German study support and expand upon the recently disclosed early results from the corresponding U.S. trial with BNT162b1.

Preliminary data for BNT162b1 in the German Phase 1/2 trial were evaluated with a total of 60 healthy adults 18 to 55 years of age enrolled in the study. Of these 60 participants, 12 subjects per dose level (1 µg, 10 µg, 30 µg, and 50 µg; 48 participants in total) were vaccinated with BNT162b1 on day 1 and day 22 (n=12 per prime-boost cohort, except n=11 for the 10 µg and 50 µg cohorts from day 22 on). Furthermore, 12 participants received a single injection of 60 µg.

The vaccine elicited high, dose level-dependent SARS-CoV-2-neutralizing titers and RBD-binding IgG concentrations after the second dose. Day 43 SARS-CoV-2 neutralizing geometric mean titers were in the range of 0.7-fold (1 µg) to 3.2-fold (50 µg) compared to that of a panel of SARS-CoV-2 infection convalescent human sera. Furthermore, sera of vaccinated subjects displayed broadly neutralizing activity in pseudovirus neutralization assays across a panel of sixteen SARS-CoV-2 RBD variants represented in publicly available SARS-CoV-2 sequences and against the newly dominant D614G strain.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/167652 .

Major Points in Table of Contents:

1 Celecoxib Product Definition
2 Global Celecoxib Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Celecoxib Shipments
2.2 Global Manufacturer Celecoxib Business Revenue
2.3 Global Celecoxib Market Overview
3 Manufacturer Celecoxib Business Introduction
3.1 Pfizer Celecoxib Business Introduction
3.1.1 Pfizer Celecoxib Shipments, Price, Revenue and Gross profit 2020-2025
3.1.2 Pfizer Celecoxib Business Distribution by Region
3.1.3 Pfizer Interview Record
3.1.4 Pfizer Celecoxib Business Profile
3.1.5 Pfizer Celecoxib Product Specification
3.2 Shire Celecoxib Business Introduction
3.2.1 Shire Celecoxib Shipments, Price, Revenue and Gross profit 2020-2025
3.2.2 Shire Celecoxib Business Distribution by Region
3.2.3 Interview Record
3.2.4 Shire Celecoxib Business Overview
3.2.5 Shire Celecoxib Product Specification
3.3 Teva Celecoxib Business Introduction
3.3.1 Teva Celecoxib Shipments, Price, Revenue and Gross profit 2020-2025
3.3.2 Teva Celecoxib Business Distribution by Region
3.3.3 Interview Record
3.3.4 Teva Celecoxib Business Overview
3.3.5 Teva Celecoxib Product Specification
3.4 Mylan Celecoxib Business Introduction
3.5 Chengdu Suncadia Pharmaceuticals Celecoxib Business Introduction
3.6 Jiangsu Chiatai Qingjiang Pharmaceutical Celecoxib Business Introduction
………………. Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.